What is Retatrutide?
Retatrutide (LY3437943) is a 39-amino acid triple receptor co-agonist simultaneously activating GLP-1R, GIPR, and GCGR. GCGR activation adds thermogenesis, fatty acid oxidation, and hepatic glucose production modulation beyond dual GIP+GLP-1 agonism. Phase 2 (NEJM 2023): 24.2% mean weight reduction at 48 weeks at the 12mg dose. The 120mg vial format delivers 1,200mg total per 10-vial kit for extended research protocols. Research use only.
Research Applications
Triple Receptor Pharmacology
GLP-1R + GIPR + GCGR co-agonism — additive and synergistic receptor biology vs dual agonists
GCGR-Mediated Thermogenesis
Isolated glucagon receptor contribution to energy expenditure, fat oxidation, and hepatic glucose
Obesity & Body Weight Models
Phase 2 NEJM 2023 reference compound — 24.2% mean weight loss at 48 weeks
NASH / Hepatic Fat
GCGR signalling in hepatic steatosis, liver fat reduction, and NASH models
Dose-Volume Efficiency Research
120mg/vial format — high total peptide loading per kit for extended dose-response studies
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | Not publicly standardized (LY3437943) |
| Molecular Formula | Large synthetic peptide — sequence-specific |
| Peptide Type | Triple Receptor Agonist (GLP-1R / GIPR / GCGR) |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | −20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months (unopened) |

